急性髓细胞白血病靶向治疗的进展

摘要

Advances in understangding the biology of acute leukemia and identification of mutaions have made a indicating that the coming of targeted therapy. A number of molecular markers have been description . It,s well known that fms like tyrosine kinase 3,RAS/RAF/MEK/ERK、JaK-2、CXCR4、CD33、have been studied well. In this paper,the research process of molecular biology characteristics and targeted therapies were reviewed.%　　随着人们对急性髓细胞白血病（AML）分子生物学不断认识及突变基因不断发现，预示着将来可能是以分子为靶点治疗的新时代。现有大量的突变基因和分子路径已经被描述，其中研究的最多的分子包括：III型受体型酪氨酸激酶（fms like tyrosine kinase 3，flt3）、RAS/RAF/MEK/ERK、JAK-2、cxcr4、cd33等。这篇文章综述AML的分子生物学特性，分子为靶点治疗方案的发展。